Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Net Income towards Common Stockholders: 2019-2025

Historic Net Income towards Common Stockholders for BridgeBio Pharma (BBIO) over the last 7 years, with Sep 2025 value amounting to -$182.7 million.

  • BridgeBio Pharma's Net Income towards Common Stockholders fell 12.78% to -$182.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$797.1 million, marking a year-over-year decrease of 81.63%. This contributed to the annual value of -$535.8 million for FY2024, which is 16.70% up from last year.
  • According to the latest figures from Q3 2025, BridgeBio Pharma's Net Income towards Common Stockholders is -$182.7 million, which was down 0.46% from -$181.9 million recorded in Q2 2025.
  • In the past 5 years, BridgeBio Pharma's Net Income towards Common Stockholders ranged from a high of -$9.9 million in Q2 2022 and a low of -$265.1 million during Q4 2024.
  • For the 3-year period, BridgeBio Pharma's Net Income towards Common Stockholders averaged around -$155.5 million, with its median value being -$167.4 million (2025).
  • Per our database at Business Quant, BridgeBio Pharma's Net Income towards Common Stockholders skyrocketed by 89.77% in 2022 and then tumbled by 1,502.06% in 2023.
  • Quarterly analysis of 5 years shows BridgeBio Pharma's Net Income towards Common Stockholders stood at -$147.2 million in 2021, then increased by 6.51% to -$137.6 million in 2022, then declined by 22.21% to -$168.1 million in 2023, then tumbled by 57.63% to -$265.1 million in 2024, then decreased by 12.78% to -$182.7 million in 2025.
  • Its Net Income towards Common Stockholders was -$182.7 million in Q3 2025, compared to -$181.9 million in Q2 2025 and -$167.4 million in Q1 2025.